

**CLAIMS**

1. The use of a GABA<sub>B</sub> receptor antagonist for increasing neurotrophin levels in the CNS.

2. The use of a GABA<sub>B</sub> receptor antagonist for the treatment of a condition responsive to an increase of neurotrophin levels in the CNS.

3. The use of a GABA<sub>B</sub> receptor antagonist for the treatment of neurodegeneration.

4. The use of a GABA<sub>B</sub> receptor antagonist for the treatment of Parkinson's disease, amyotrophic lateral sclerosis and stress-induced neurodegeneration.

5. The use of a GABA<sub>B</sub> receptor antagonist for suppression of immune responses following CNS tissue grafts.

6. The use of a GABA<sub>B</sub> receptor antagonist for the manufacture of a pharmaceutical composition responsive to an increase of neurotrophin levels in the CNS.

*Sub A2* | 7. The use according to any one of claims 1 to 6 for increasing NGF and BDNF.

8. A pharmaceutical composition comprising a GABA<sub>B</sub> receptor antagonist in association with at least one pharmaceutical carrier or diluent, for use in the treatment of a condition responsive to an increase of neurotrophin levels in the CNS.

9. A method for increasing neurotrophin levels in the CNS of a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a GABA<sub>B</sub> receptor antagonist.

10. A method for treating a condition responsive to an increase of neurotrophin levels in the CNS, in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a GABA<sub>B</sub> receptor antagonist.

11. A method for treating neurodegeneration or for suppression of immune responses following CNS tissue grafts in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a GABA<sub>B</sub> receptor antagonist.

*Add A37*

PROSTEGON TAB 250  
00000000000000000000